A sole dosage may potentially eradicate cancer.
Stanford University Researchers Develop Targeted Cancer Treatment
Stanford University School of Medicine has announced a groundbreaking development in cancer treatment: a targeted injection that has proven effective in eliminating tumors in mice. This new approach could lead to more effective treatments for various types of cancer.
In recent years, research efforts have focused on finding more efficient methods to combat cancer, offering new hope with innovations such as nanotechnology, engineered microbes, and starvation techniques.
The latest study, led by senior study author Dr. Ronald Levy, investigates the potential of a new approach called a "one-time application" of two agents directly into a malignant solid tumor.
Dr. Levy, a specialist in immunotherapy, explains that this method stimulates the body's immune response without the need for wholesale activation or customization of a patient's immune cells.
So far, the studies using mice have shown promising results, with the elimination of tumors throughout the body when both agents are used together. The researchers believe this method could quickly move towards clinical trials, as one of the agents has already been approved for human therapy, and the other is currently under clinical trial for lymphoma treatment.
The study was published yesterday in the journal Science Translational Medicine.
Dr. Levy's team delivered micrograms of two specific agents into a hard tumor site in each affected mouse. These agents boost the immune cells' ability to express a receptor called OX40, found on T cells, and activate T cells, causing them to migrate and destroy other tumors.
The approach has the potential to target several types of cancer, as the T cells will "learn" to deal with the specific type of cancer cell they have been exposed to. The team achieved successful results in mice with lymphoma, breast, colon, and skin cancer models, as well as those engineered to develop breast cancer spontaneously.
Although some cancer cells have complex ways of evading the immune system, this method appears to effectively teach immune cells how to fight against those specific types of cancer cells. Mixed results were observed when transplanting two different types of cancer tumors in the same animal; only the tumor sharing the same protein targets as the treated site was affected.
This targeted approach, according to Dr. Levy, attacks specific cancer cells without identifying the exact proteins the T cells are recognizing. The team is now preparing a clinical trial to test the effectiveness of this treatment in people with low-grade lymphoma, with hopes of extending this therapy to various types of cancer tumors in humans.
Researchers at Stanford University School of Medicine have been at the forefront of developing targeted immune response therapies for cancer, particularly through advances in engineered T cell therapies such as CAR-T cell and T cell receptor (TCR) therapies. Although the "one-time application" method does not precisely refer to a single, widely publicized clinical regimen, it likely refers to some of their innovative immunotherapy protocols.
- The new "one-time application" approach, developed by Stanford University School of Medicine, stimulates the immune system to eliminate various types of cancer, such as lymphoma, breast, colon, and skin cancer.
- This targeted treatment, under clinical trial for lymphoma treatment, works by boosting immune cells' ability to express a receptor called OX40 and activate T cells, enabling them to migrate and destroy other tumors.
- The science behind this treatment could lead to new medical-condition therapies and treatments, as it teaches immune cells to combat specific cancer cells without a wholesale activation or customization of a patient's immune cells.
- As part of the ongoing health-and-wellness research, researchers at Stanford University School of Medicine are now preparing a clinical trial to test the effectiveness of this treatment in people with low-grade lymphoma, with possibilities of extending it to other types of cancer tumors in humans.
